Ariosa Diagnostics

What Ariosa Diagnostics does

Ariosa Diagnostics is a molecular diagnostics company founded in 2009 and headquartered in San Jose, California, that developed the Harmony Prenatal Test, a cell-free DNA (cfDNA)-based non-invasive prenatal test (NIPT). The test analyzes fetal DNA fragments in maternal blood from a single blood draw as early as 10 weeks of pregnancy to screen for the most common chromosomal conditions, specifically Trisomy 21, 18, and 13, sex chromosome aneuploidies, and 22q11.2 microdeletion. Ariosa serves two principal segments: expecting parents seeking early, low-risk screening as an alternative to invasive diagnostic procedures such as amniocentesis or chorionic villus sampling, and obstetricians, gynecologists, and other healthcare providers who order the test through their clinical practices.

The underlying technology is built on Ariosa's proprietary DANSR methodology for cfDNA analysis, with a clinical evidence base of 80 peer-reviewed published studies as of January 2025 — among the most validated NIPT offerings globally. The test is operated as a laboratory-developed test (LDT) with CE-IVD marking, and the Harmony and DANSR trademarks are registered intellectual property. Headcount is reported at 51–100 employees, consistent with a focused clinical laboratory operation rather than a broad consumer-facing business.

Ariosa's go-to-market operates as a B2B clinical channel model: tests are ordered by clinicians and processed in laboratory settings for distribution to patients. Ariosa was acquired by Roche and now operates as a wholly-owned subsidiary of Roche Diagnostics, with the Harmony test marketed through Roche's global diagnostics commercial infrastructure. The company has historically raised approximately $67.5 million across three institutional rounds (2009, 2010, and 2012) from Domain Associates, Meritech Capital Partners, and Venrock, with John Stuelpnagel serving as Executive Chairman. Pricing is not publicly disclosed.

Name

Ariosa Diagnostics

Legal name

Ariosa Diagnostics

Website

https://ariosadx.com

Company type

Private

Founded year

2009

Operating status

Acquired

Headcount range

51–100 employees

Short description

Ariosa Diagnostics is a San Jose-based molecular diagnostics company that developed the Harmony Prenatal Test, a cell-free DNA-based non-invasive prenatal screen. Founded in 2009 and now a Roche subsidiary, it serves obstetricians and expecting parents globally.

Ownership category

akta.pro rank

Product category

Non-invasive Prenatal Testing (NIPT)

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI)

akta.pro secondary industries

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ), Genetic & Prenatal Testing Laboratories (HLAFAMAH), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

Keywords

• Non-invasive prenatal testing
• Cell-free DNA analysis
• Prenatal screening
• Molecular diagnostics
• Chromosomal aneuploidy testing

Headquarters

HQ city

San Jose

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Distribution channels1 record

Marketing channels3 records

Core offering

Ariosa Diagnostics develops and offers the Harmony Prenatal Test, a cell-free DNA (cfDNA)-based non-invasive prenatal test (NIPT) that screens for chromosomal conditions including Trisomy 21, 18, and 13, sex chromosome aneuploidies, and 22q11.2 microdeletion. The test requires only a single maternal blood draw and can be performed as early as 10 weeks of pregnancy, providing a lower-risk screening alternative to invasive diagnostic procedures such as amniocentesis and chorionic villus sampling (CVS). The test is performed as a laboratory-developed test (LDT) and is CE-IVD marked.

Differentiator

Problem solved

Functional benefit

Products and services

• Harmony Prenatal Test Cell-free DNA-based non-invasive prenatal test (NIPT) that screens for common chromosomal conditions (Trisomy 21, 18, 13), sex chromosome aneuploidies, and 22q11.2 microdeletion. Performed using a single maternal blood draw as early as 10 weeks of pregnancy and offered to patients through their healthcare providers (obstetricians, gynecologists, and other prenatal care clinicians).

Quantifiable outcome

• 80 peer-reviewed published studies demonstrating accuracy as of January 2025

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Quest Diagnostics: Large reference laboratory offering the QNatal Advanced NIPT among its women's health services, providing clinicians with an alternative prenatal screening channel to Harmony.
• Illumina: Major sequencing platform provider whose VeriSeq NIPT solution and broader genomics ecosystem compete with Roche/Ariosa in the cfDNA-based prenatal testing market, with deep installed-base and reagent advantages.
• PerkinElmer: Diagnostics and life sciences company with prenatal and newborn screening products (e.g., Vanadis NIPT platform) that compete with Roche/Ariosa in reproductive genetic screening workflows.
• Myriad Genetics: Genetic testing company with women's health and reproductive testing offerings (e.g., Foresight carrier screen) that intersect with Harmony's clinical and patient markets, particularly through OB/GYN channels.
• Hologic: Women's health-focused diagnostics company whose prenatal and molecular diagnostics portfolio overlaps with Harmony in OB/GYN and reproductive health testing channels.
• Laboratory Corporation of America (LabCorp): Acquired Sequenom and offers the MaterniT21 NIPT alongside a broad clinical laboratory menu, competing with Harmony for clinician-ordered prenatal screening volume in the U.S.

Others

• Bio-Techne: Life sciences tools and diagnostics company with reagents and exosome/DNA-based assay components used across the NIPT and reproductive diagnostics value chain, including suppliers and partners in the cfDNA testing ecosystem.

Regional players

• BGI Genomics: China-based genomics company offering NIPT services (NIFTY) globally, representing a major international competitor to Harmony, especially in Asia and emerging markets where Roche is also expanding.

Direct peers

• Natera: Direct NIPT competitor offering the Panorama prenatal test using cfDNA technology to screen for common chromosomal conditions, microdeletions, and twin pregnancies, targeting the same clinicians and patient population as Harmony.

Emerging players

• Invitae: Genetic information company offering reproductive and prenatal genetic testing (carrier screening and non-invasive options) that compete with Harmony in the women's health genetic testing space.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/HarmonyPrenatal
• YouTubeyoutube.com/user/roche
• Facebookfacebook.com/HarmonyPrenatal
• LinkedInlinkedin.com/company/1138294

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ariosa Diagnostics